Testosterone undecanoate | CAS#5949-44-0 | metabolite of Testosterone

MedKoo Cat#: 596169 | Name: Testosterone undecanoate

Description:

WARNING: This product is for research use only, not for human or veterinary use.

NOTE: Testosterone undecanoate has been discontinued. | Testosterone undecanoate is a metabolite of Testosterone, which is a promising androgen for male hormonal contraception.

Chemical Structure

Testosterone undecanoate

CAS#5949-44-0

Theoretical Analysis

MedKoo Cat#: 596169

Name: Testosterone undecanoate

CAS#: 5949-44-0

Chemical Formula: C30H48O3

Exact Mass: 456.3603

Molecular Weight: 456.71

Elemental Analysis: C, 78.90; H, 10.59; O, 10.51

Price and Availability

This product was removed for the commercial reasons.

Related CAS #

No Data

Synonym

Testosterone undecanoate; Jatenzo; T undecanoate; Undestor; BRN 3176734; BRN-3176734; BRN3176734;

IUPAC/Chemical Name

(8R,9S,10R,13S,14S,17S)-10,13-dimethyl-3-oxo-2,3,6,7,8,9,10,11,12,13,14,15,16,17-tetradecahydro-1H-cyclopenta[a]phenanthren-17-yl undecanoate

InChi Key

UDSFVOAUHKGBEK-CNQKSJKFSA-N

InChi Code

InChI=1S/C30H48O3/c1-4-5-6-7-8-9-10-11-12-28(32)33-27-16-15-25-24-14-13-22-21-23(31)17-19-29(22,2)26(24)18-20-30(25,27)3/h21,24-27H,4-20H2,1-3H3/t24-,25-,26-,27-,29-,30-/m0/s1

SMILES Code

C[C@@]12[C@@H](OC(CCCCCCCCCC)=O)CC[C@@]1([H])[C@]3([H])CCC4=CC(CC[C@]4(C)[C@@]3([H])CC2)=O

Appearance

Solid powder

Purity

>98% (or refer to the Certificate of Analysis)

Shipping Condition

Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition

Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility

Soluble in DMSO

Shelf Life

>2 years if stored properly

Drug Formulation

This drug may be formulated in DMSO

Stock Solution Storage

0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code

2934.99.9001

More Info

Instruction

View handling instruction

Preparing Stock Solutions

The following data is based on the product molecular weight 456.71 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Concentration / Solvent Volume / Mass	1 mg	5 mg	10 mg
1 mM	1.15 mL	5.76 mL	11.51 mL
5 mM	0.23 mL	1.15 mL	2.3 mL
10 mM	0.12 mL	0.58 mL	1.15 mL
50 mM	0.02 mL	0.12 mL	0.23 mL

1: Huh JS, Chung BH, Hong CH, Ryu JK, Kim JH, Han WK, Park KK. The effects of testosterone replacement on penile structure and erectile function after long-term castration in adult male rats. Int J Impot Res. 2018 May 4. doi: 10.1038/s41443-017-0010-6. [Epub ahead of print] PubMed PMID: 29725076. 2: DI HJ, Fan YF, Zhang HF, Liu KM, Liu C. [Testosterone Undecanoate Pills improves insulin resistance in type-2 diabetes men with hypogonadism]. Zhonghua Nan Ke Xue. 2017 Jun;23(6):517-521. Chinese. PubMed PMID: 29722943. 3: Mao JB, Chen XG, Gui DW, Peng W, Zheng J. [Oral Testosterone Undecanoate Capsules combined with Qilin Pills for late-onset hypogonadism in males]. Zhonghua Nan Ke Xue. 2017 May;23(5):455-458. Chinese. PubMed PMID: 29717839. 4: Groti K, Žuran I, Antonič B, Foršnarič L, Pfeifer M. The impact of testosterone replacement therapy on glycemic control, vascular function, and components of the metabolic syndrome in obese hypogonadal men with type 2 diabetes. Aging Male. 2018 Apr 30:1-12. doi: 10.1080/13685538.2018.1468429. [Epub ahead of print] PubMed PMID: 29708829. 5: Zagarskikh EY, Proshchai GA, Vorokhobina NV. [Fibroblast growth factor-21 as a marker of premature aging in young and middled-aged men with type 2 diabetes]. Urologiia. 2018 Mar;(1):92-95. Russian. PubMed PMID: 29634140. 6: Defreyne J, Vantomme B, Van Caenegem E, Wierckx K, De Blok CJM, Klaver M, Nota NM, Van Dijk D, Wiepjes CM, Den Heijer M, T'Sjoen G. Prospective evaluation of hematocrit in gender-affirming hormone treatment: results from European Network for the Investigation of Gender Incongruence. Andrology. 2018 Mar 30. doi: 10.1111/andr.12485. [Epub ahead of print] PubMed PMID: 29602229. 7: Hua Y, Li W, Cheng Z, Zhao Z, Yin X, Li Y, Sun J, Gao J, Zhang H, Zheng A. Solidification of Nanostructured Lipid Carriers Loaded Testosterone Undecanoate: In Vivo and In Vitro Study. Drug Res (Stuttg). 2018 Mar 27. doi: 10.1055/a-0573-9132. [Epub ahead of print] PubMed PMID: 29589341. 8: Kotwal N, Upreti V, Nachankar A, Hari Kumar KVS. A Prospective, Observational Study of Osteoporosis in Men. Indian J Endocrinol Metab. 2018 Jan-Feb;22(1):62-66. doi: 10.4103/ijem.IJEM_414_16. PubMed PMID: 29535939; PubMed Central PMCID: PMC5838913. 9: Dimitriadis GK, Randeva HS, Aftab S, Ali A, Hattersley JG, Pandey S, Grammatopoulos DK, Valsamakis G, Mastorakos G, Jones TH, Barber TM. Metabolic phenotype of male obesity-related secondary hypogonadism pre-replacement and post-replacement therapy with intra-muscular testosterone undecanoate therapy. Endocrine. 2018 Apr;60(1):175-184. doi: 10.1007/s12020-017-1516-x. Epub 2018 Feb 2. PubMed PMID: 29396841; PubMed Central PMCID: PMC5845623. 10: Ng Tang Fui M, Hoermann R, Grossmann M. Effect of Testosterone Treatment on Adipokines and Gut Hormones in Obese Men on a Hypocaloric Diet. J Endocr Soc. 2017 Feb 28;1(4):302-312. doi: 10.1210/js.2017-00062. eCollection 2017 Apr 1. PubMed PMID: 29264488; PubMed Central PMCID: PMC5686636. 11: Levcikova M, Breza J Jr, Luha J, Dubravicky J, Kovacova E, Fillo J. Testosterone replacement therapy (TRT) and its effect on bone marrow. How serious is it and is there a true polyglobulia? Bratisl Lek Listy. 2017;118(11):654-657. doi: 10.4149/BLL_2017_124. PubMed PMID: 29216720. 12: Lood Y, Aardal-Eriksson E, Webe C, Ahlner J, Ekman B, Wahlberg J. Relationship between testosterone in serum, saliva and urine during treatment with intramuscular testosterone undecanoate in gender dysphoria and male hypogonadism. Andrology. 2018 Jan;6(1):86-93. doi: 10.1111/andr.12435. Epub 2017 Nov 16. PubMed PMID: 29145707. 13: Correction to: Wolf et al., Effectiveness and tolerability of parenteral testosterone undecanoate: a post-marketing surveillance study. Aging Male. 2017 Dec;20(4):i. doi: 10.1080/13685538.2017.1380904. Epub 2017 Sep 28. PubMed PMID: 28956684. 14: Wolf J, Keipert D, Motazedi H, Ernst M, Nettleship J, Gooren L. Effectiveness and tolerability of parenteral testosterone undecanoate: a post-marketing surveillance study. Aging Male. 2017 Dec;20(4):225-234. doi: 10.1080/13685538.2017.1364234. Epub 2017 Aug 16. PubMed PMID: 28812471. 15: Hackett G, Cole N, Saghir A, Jones P, Strange RC, Ramachandran S. Testosterone replacement therapy: improved sexual desire and erectile function in men with type 2 diabetes following a 30-week randomized placebo-controlled study. Andrology. 2017 Sep;5(5):905-913. doi: 10.1111/andr.12399. Epub 2017 Aug 3. PubMed PMID: 28771964. 16: Krakowsky Y, Conners W, Davidson E, Rawji A, Morgentaler A. Initial Clinical Experience With Testosterone Undecanoate Therapy (AVEED) in Men With Testosterone Deficiency in the United States. Urology. 2017 Nov;109:27-31. doi: 10.1016/j.urology.2017.07.007. Epub 2017 Jul 19. PubMed PMID: 28735014. 17: Haider KS, Haider A, Doros G, Traish A. Long-Term Testosterone Therapy Improves Urinary and Sexual Function, and Quality of Life in Men with Hypogonadism: Results from a Propensity Matched Subgroup of a Controlled Registry Study. J Urol. 2018 Jan;199(1):257-265. doi: 10.1016/j.juro.2017.07.039. Epub 2017 Jul 18. PubMed PMID: 28728990. 18: Ergün O, Koşar PA, Onaran İ, Darici H, Koşar A. Lysozyme gene treatment in testosterone induced benign prostate hyperplasia rat model and comparasion of its' effectiveness with botulinum toxin injection. Int Braz J Urol. 2017 Nov-Dec;43(6):1167-1175. doi: 10.1590/S1677-5538.IBJU.2016.0677. PubMed PMID: 28727388; PubMed Central PMCID: PMC5734082. 19: Velho I, Fighera TM, Ziegelmann PK, Spritzer PM. Effects of testosterone therapy on BMI, blood pressure, and laboratory profile of transgender men: a systematic review. Andrology. 2017 Sep;5(5):881-888. doi: 10.1111/andr.12382. Epub 2017 Jul 14. PubMed PMID: 28709177. 20: Aranda G, Fernández-Rebollo E, Pradas-Juni M, Hanzu FA, Kalko SG, Halperin I, Mora M. Effects of sex steroids on the pattern of methylation and expression of the promoter region of estrogen and androgen receptors in people with gender dysphoria under cross-sex hormone treatment. J Steroid Biochem Mol Biol. 2017 Sep;172:20-28. doi: 10.1016/j.jsbmb.2017.05.010. Epub 2017 May 21. PubMed PMID: 28539237.